<DOC>
	<DOCNO>NCT01728363</DOCNO>
	<brief_summary>Multiple center , open-label , PK study</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Antistaphylococcal Antibiotics Infants ( NICHD-2012-02-Staph Trio )</brief_title>
	<detailed_description>Pharmacokinetics rifampin , ticarcillin-clavulanate , clindamycin antibiotic hospitalize infant suspect systemic infection receive one study drug per local standard care . Number participant 16-32 evaluable per study drug rifampin , ticarcillin-clavulanate , clindamycin antibiotic .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Ticarcillin-clavulanic acid</mesh_term>
	<mesh_term>Ticarcillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Sufficient intravascular access Suspected systemic infection receive 1 study drug per standard care inform consent legal guardian history allergic reaction study drug urine output &lt; 0.5 mL/hr/kg prior 24 hour serum creatinine &gt; 1.7 mg/dl Any condition investigator judgment precludes participation could affect participant safety</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>32 Weeks</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Staphylococcal</keyword>
</DOC>